These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32526482)

  • 1. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
    Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
    Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
    PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
    Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
    Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
    Huard K; Smith AC; Cappon G; Dow RL; Edmonds DJ; El-Kattan A; Esler WP; Fernando DP; Griffith DA; Kalgutkar AS; Ross TT; Bagley SW; Beebe D; Bi YA; Cabral S; Crowley C; Doran SD; Dowling MS; Liras S; Mascitti V; Niosi M; Pfefferkorn JA; Polivkova J; Préville C; Price DA; Shavnya A; Shirai N; Smith AH; Southers JR; Tess DA; Thuma BA; Varma MV; Yang X
    J Med Chem; 2020 Oct; 63(19):10879-10896. PubMed ID: 32809824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
    Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
    Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
    Lawitz EJ; Li KW; Nyangau E; Field TJ; Chuang JC; Billin A; Wang L; Wang Y; Huss RS; Chung C; Subramanian GM; Myers RP; Hellerstein MK
    J Lipid Res; 2022 Sep; 63(9):100250. PubMed ID: 35835205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
    Neokosmidis G; Cholongitas E; Tziomalos K
    World J Gastroenterol; 2021 Oct; 27(39):6522-6526. PubMed ID: 34754150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH).
    Sivakumar P; Saul M; Robinson D; King LE; Amin NB
    Sci Rep; 2024 Jul; 14(1):17072. PubMed ID: 39048608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The L-α-Lysophosphatidylinositol/G Protein-Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis.
    Fondevila MF; Fernandez U; Gonzalez-Rellan MJ; Da Silva Lima N; Buque X; Gonzalez-Rodriguez A; Alonso C; Iruarrizaga-Lejarreta M; Delgado TC; Varela-Rey M; Senra A; Garcia-Outeiral V; Novoa E; Iglesias C; Porteiro B; Beiroa D; Folgueira C; Tojo M; Torres JL; Hernández-Cosido L; Blanco Ó; Arab JP; Barrera F; Guallar D; Fidalgo M; López M; Dieguez C; Marcos M; Martinez-Chantar ML; Arrese M; Garcia-Monzon C; Mato JM; Aspichueta P; Nogueiras R
    Hepatology; 2021 Feb; 73(2):606-624. PubMed ID: 32329085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study.
    Stiede K; Miao W; Blanchette HS; Beysen C; Harriman G; Harwood HJ; Kelley H; Kapeller R; Schmalbach T; Westlin WF
    Hepatology; 2017 Aug; 66(2):324-334. PubMed ID: 28470676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
    Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
    Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The chloroform extract of Cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats.
    Lin Z; Wu ZF; Jiang CH; Zhang QW; Ouyang S; Che CT; Zhang J; Yin ZQ
    Phytomedicine; 2016 Nov; 23(12):1475-1483. PubMed ID: 27765368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
    Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
    Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation.
    Li H; Ying H; Hu A; Hu Y; Li D
    Biol Pharm Bull; 2017; 40(5):650-657. PubMed ID: 28458350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice.
    Gao YS; Qian MY; Wei QQ; Duan XB; Wang SL; Hu HY; Liu J; Pan CY; Zhang SQ; Qi LW; Zhou JP; Zhang HB; Wang LR
    Acta Pharmacol Sin; 2020 Mar; 41(3):336-347. PubMed ID: 31645659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bacteria-derived tetramerized protein ameliorates nonalcoholic steatohepatitis in mice via binding and relocating acetyl-coA carboxylase.
    Lin Y; Yang M; Huang L; Yang F; Fan J; Qiang Y; Chang Y; Zhou W; Yan L; Xiong J; Ping J; Chen S; Men D; Li F
    Cell Rep; 2023 Nov; 42(11):113453. PubMed ID: 37976162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma.
    Lally JSV; Ghoshal S; DePeralta DK; Moaven O; Wei L; Masia R; Erstad DJ; Fujiwara N; Leong V; Houde VP; Anagnostopoulos AE; Wang A; Broadfield LA; Ford RJ; Foster RA; Bates J; Sun H; Wang T; Liu H; Ray AS; Saha AK; Greenwood J; Bhat S; Harriman G; Miao W; Rocnik JL; Westlin WF; Muti P; Tsakiridis T; Harwood HJ; Kapeller R; Hoshida Y; Tanabe KK; Steinberg GR; Fuchs BC
    Cell Metab; 2019 Jan; 29(1):174-182.e5. PubMed ID: 30244972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.